B. Infantis Supplementation to Improve Immunity in Infants Exposed to HIV

Recruiting N/A Interventional Study
Hiv Vaccine Reaction Microbial Colonization Infant Development
Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 Days – 50
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
200 (estimated)
Sponsor
University of Cape Town · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The primary objectives of this study are to evaluate the effect of early-life B. infantis Rosell®-33 supplementation in infants exposed to HIV on: * gut microbiome composition and diversity at 4 weeks of life * markers of intestinal inflammation and microbial translocation at 4 weeks of life * Th1 cytokine responses to BCG at 7 weeks and 36 weeks of life The secondary objectives include to evalu…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria Mother: * Willing and able to provide signed and dated informed consent form * 18 years of age or older * Documented HIV seropositive * Antiretroviral therapy initiated before the third trimester of pregnancy * Planning on exclusively breastfeeding the infant for the first 6 mont…
Contacts

Heather Jaspan, MD PHD

2068543336

hbjaspan@gmail.com

CONTACT

Anna-Ursula Happel, PhD

+ 27 21 406 6823

anna.happel@uct.ac.za

CONTACT